Tetra-PEG hydrogels based on the ammonolysis reaction between tetra-armed poly(ethylene glycol) amine (Tetra-PEG-NH2) and Tetra-PEG-SAE offer massive advantages as sealants. They are entirely synthetic without the misgivings of being inhibited by anticoagulation agents and transferring disease. Their cost is low due to their easily preservable components with high accessibility. Because of the intrinsic properties of this ammonolysis reaction, the resulting hydrogels can gel  fast just by injection and adhere to the tissues tightly throughchemical bonds. Another remarkable advantage for Tetra-PEG hydrogels is that they are mechanically tough, and the sealants are favored to be mechanically tough to keep stable in case of dynamic movement of the tissues and the use of assistant pressure which is a key adjunctive step in achieving hemostasis. However, two hurdles are preventing extending their applications in vivo. The first one is that just as commercialized sealants, none of the reported Tetra-PEG hydrogels could be controllably removed without mechanical debridement, which is extremely dangerous because of their high mechanical strength. Besides, they possess long degradation time, which will lead to severe foreign body reactions, tissue adhesion, disturbed tissue healing, and obstruction of the circulatory system, when used in vivo. Here, to overcome the limitations of the existing ammonolysis based Tetra-PEG hydrogels, we construct an optimized one (SS) with fast degradable and controllably dissolvable properties via Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl succinate (Tetra-PEG-SS) . The resulting SS exhibits biocompatibility superior to the reported degradable Tetra-PEG hydrogel (SG) based on Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl glutarate (Tetra-PEG-SG) . More importantly, in contrast to the disappointing results of SG that leads to serious adverse effects in in vivo hemostasis due to the long retention, SS causes almost no noticeable side effects with outstanding hemostasis efficacy even under the anticoagulated situations. This hydrogel is a promising candidate for the next-generation in vivo sealants in the aged society.

CPhI China 2019 was held successfully in Shanghai, China from June 18th-20th. We Sinopeg sent a very professional sales team to participate this exhibition. Our booth Number is W4F21. During the exhibition, we had very deep disscuion with old partner, and customers from all over the world came to  consult the company's products，we obtained the approval and praise from our customers. Looking forward to see you again next year, CPhI China 2020 in Shanghai.

Warmly welcome you to visit our booth 1D73 in API  (Hangzhou) from May. 8th to May. 10th, 2019. Exhibition name: the 82nd API China- China international pharmaceutical raw materials, intermediates, packaging, equipment fair. Booth number:1D73 Time: May 8-10,2019 Venue: Hangzhou international expo center We provided a wealth of polyethylene glycol derivatives, side chains of hypoglycemic drugs (Semaglutide side chain, Liraglutide side chain, Insulin Detemir side chain, Insulin Deglutide chain), polyethylene glycol block copolymers, polyethylene glycol phospholipids, etc. Welcome to our booth.

Welcome to visit us at

Recently, SINOPEG's self-developed products, mPEG-DTA-1 and HO-PEG-DTA-5, have been formally granted European patents! This marks the recognition of domestically produced high-end LNP excipients by the international regulatory system, laying a solid foundation for China's innovative drugs to enter the global market! As core components of the LNP delivery system, the structure of PEG lipids decisively influences the safety, stability, and immunogenicity of the formulation. SINOPEG has always been committed to the research and development of new technologies and products, and has already secured a significant position in the field of domestic PEG lipid R&D. The newly authorized mPEG-DTA-1 and HO-PEG-DTA-5 are important achievements of the company's continuous innovation in the PEG lipid field. Innovation Breakthrough: mPEG-DTA-1 and HO-PEG-DTA-5 Granted European Patents HO-PEG-DTA-5 is a PEG lipid containing a hydroxyl terminal, which, together with its structural counterpart mPEG-DTA-1, forms the core layout of SINOPEG's product series in this category. To date, these two products have completed their global intellectual property layout: they obtained Chinese patent authorization back in 2023 (Patent No.: ZL202280003648.7) and recently received European patent authorization. (Screenshot source: European Patent Office, Link: https://register.epo.org/application?number=EP22784092&tab=main) Meanwhile, the independently developed mPEG-DTA-1 has already completed its filing with the CDE (Filing No.: F20230000444) and DMF submission (Filing No.: 039451). Even more encouragingly, HO-PEG-DTA-5 will soon complete dual submissions in China and the US, providing strong excipient support and registration convenience for Chinese innovative pharmaceutical companies aiming for the international mainstream pharmaceutical market! Note: For more product filing information, please feel free to contact us. LNP Technology: A Revolutionary Nano-Delivery Platform Lipid Nanoparticles (LNP), as one of the most successful nano-delivery carriers, have demonstrated exceptional capabilities in delivering cytotoxic chemotherapeutic drugs, antibiotics, and nucleic acid therapeutics. In recent years, with the rapid development of mRNA vaccines and drugs, the importance of LNP technology has become increasingly prominent, making it a focal point in the global pharmaceutical field. The granting of European patents for SINOPEG's products not only reflects the international intellectual property system's recognition of China's innovative achievements but also signifies that Chinese companies are steadily moving towards the center stage in the field of high-end pharmaceutical raw materials, potentially injecting new vitality into the global development of LNP technology. Product Portfolio: Extensive Layout Meets Diverse Needs Leveraging profound technical expertise, SINOPEG has developed a variety of novel PEG-lipid structures, providing more high-quality options for glo...

This golden autumn, SINOPEG ventured to Europe with its innovative products and solutions, making consecutive appearances at two premier international industry exhibitions within two months, engaging in deep exchanges with global pharmaceutical elites. CPHI Frankfurt 2025 (Frankfurt, Germany, Oct 28-30) As the world's largest and most influential professional event for the pharmaceutical industry, CPHI Frankfurt brought together industry elites from across the globe. In this grand gathering, SINOPEG attracted numerous visitors with its professional technical sharing. During the exhibition, we prominently showcased our latest achievements in areas such as in vivo CAR-T delivery, Antibody-Drug Conjugate (ADC) linkers, and block copolymers. We held in-depth discussions with multiple potential clients and partners from Europe, North America, and Asia! Many international clients praised our continuously improving R&D capabilities and product quality control system. TIDES Europe 2025 (Basel, Switzerland, Nov 11-13) Following closely, we moved to Switzerland to participate in TIDES Europe, an exhibition focused on oligonucleotides, peptides, mRNA therapies, and related fields. As one of the fastest-growing segments in biopharmaceuticals, TIDES provided us with a valuable platform for direct dialogue with global top experts. Here, we shared SINOPEG's technical expertise and project experience in fatty acid-modified side chains, LNP delivery material production, and related CMC services, attracting numerous biotechnology companies seeking reliable CDMO partners in this field. Through exchanges with industry benchmark companies, we further clarified our future technological development direction and innovation priorities. The successful participation in these two consecutive exhibitions allowed us to clearly grasp the development pulse of the global pharmaceutical industry chain. We deeply felt that CDMO enterprises from China are increasingly winning the trust of the global market, thanks to their continuously enhancing technical capabilities, flexible service models, and reliable quality systems. Two expeditions, two stages of growth. We brought back customer recognition, partner trust, and market insights – all of which will be invaluable assets for SINOPEG's future development! SINOPEG's journey on the international stage has just begun. We will continue to deepen our core technologies and expand our global footprint. Next year, we will appear on broader international stages, bringing more innovative solutions 'Made in China' to the global pharmaceutical industry. Stay tuned!